Ultime notizie per Tourmaline Bio (NASDAQ:TRML) Azioni

TOURMALINE BIO INC

Tourmaline Bio

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Tourmaline Bio Inc

TOURMALINE OIL CORP by Tourmaline Oil Corp.

Tourmaline Oil Corp

Rogers Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) today announced it has received all league approvals to buy out Bell's 37.5% stake in Maple Leaf Sports &amp; Entertainment (MLSE).&nbsp; &nbsp;&nbsp; "We're pleased to have league approvals to expand our ownership of MLSE, one of the most prestigious sports and entertainment organizations in the world," said Tony Staffieri, President and CEO, Rogers. "As Canada's leading communications and entertainment company, live sports and entertainment are a critical part of our core business strategy."&nbsp;
Rogers has received approvals from the National Hockey League (NHL), National Basketball Association (NBA), Canadian Football League (CFL), Major League Soccer (MLS), and the American Hockey League (AHL) to become 75% owners of MLSE.&nbsp; &nbsp;&nbsp; The deal is subject to approval from the CRTC to acquire an additional indirect interest in Toronto Raptors Network Ltd (NBA TV Canada), representing a very small portion of the transaction. Rogers has previously received clearance from the Competition Bureau to proceed with the acquisition.&nbsp;
In September 2024, Rogers announced a deal to acquire Bell's stake in MLSE for C$4.7 billion to become majority owner of MLSE.&nbsp;

TSX:RCI

Rogers Communications Announces It Has Received All League Approvals To Buy Out Bell's 37.5% Stake In Maple Leaf Sports & Entertainment For C$4.7 Billion

News

LIMN

Liminatus Pharma Regains Nasdaq Compliance

AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) has outperformed the market over the past 5 years by 11.6% on an annualized basis producing an average annual return of 24.79%. Currently, AerCap Holdings has a market capitalization of $20.78 billion. 
Buying $1000 In AER: If an investor had bought $1000 of AER stock 5 years ago, it would be worth $2,863.39 today based on a price of $114.65 for AER at the time of writing.
<h3>AerCap Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749069018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning AerCap Holdings Stock In The Last 5 Years

Vizsla Royalties Corp. (TSXV:<a href="https://www.benzinga.com/stock/VROY#TSXV">VROY</a>, OTCQB:<a href="https://www.benzinga.com/stock/VROYF#OTCQB">VROYF</a>) ("Vizsla Royalties" or the "Company") is pleased to announce it has entered into a royalty purchase agreement dated June 4, 2025 (the "Purchase Agreement") with Grupo Minero Bacis, S.A. de C.V., pursuant to which the Company will acquire an additional 3.0% net smelter returns ("NSR") royalty (the "3.0% Royalty") on certain concessions (the "Silverstone Concessions") comprising the Panuco-Copala Silver-Gold Project ("Panuco Project") located in the State of Sinaloa, Mexico (the "Transaction"). The Panuco Project is owned and operated by Vizsla Silver Corp. ("Vizsla Silver") (TSX:<a href="https://www.benzinga.com/stock/VZLA#TSX">VZLA</a>, NYSE:<a href="https://www.benzinga.com/stock/VZLA#NYSE">VZLA</a>) and is being advanced toward production.

VZLA

Vizsla Royalties Acquires Additional 3% NSR Royalty On Silverstone Concessions Of Panuco-Copala Silver-Gold Project In Mexico From Grupo Minero Bacis; Vizsla Royalties Will Exercise Its Right To Repurchase 50% Of The 3% Royalty For $1.95M And Will Purchase The Remaining 50% Of The 3% Royalty For $38.05M, For A Total Cash Consideration Of $40M

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 160.87% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 100.00% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 58.64% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ZLDAF">Zelira Therapeutics</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDAF#OTC">ZLDAF</a>) shares closed up 26.39% at $0.28</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 20.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 19.38% at $0.58</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 8.77% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 6.95% at $0.30</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 6.61% at $1.30</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 5.88% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 5.64% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 4.88% at $0.86</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 21.21% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 9.73% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 8.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 7.27% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 6.25% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 5.56% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 4.00% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 3.33% at $0.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

CLSH

CNBX

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FFNTF

FUAPF

GBHPF

GNLN

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MGWFF

NWVCF

OILFF

RMHB

RSSFF

SOLCF

TGIFF

ZDPY

ZLDAF

Bullish Sentiment Across The Cannabis Space - Check Full Movers For June 4, 2025

ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/b45780278/chargepoint-reports-first-quarter-fiscal-year-2026-financial-results">details from the report. </a>
The Details: ChargePoint reported quarterly losses of six cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $97.64 million, which missed the Street estimate of $100.53 million and is a decrease from revenue of $107.04 million from the same period last year.
Networked charging systems revenue for the first quarter was $52.1 million, down 20% from $65.4 million in the prior year&#8217;s same quarter. Subscription revenue was $38 million, up 14% from $33.4 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Elon Musk&#8217;s Optimus Could Herald The Biggest Industry In History, Billionaire Investor Marc Andreessen Says</a>
&#8220;In Q1, ChargePoint continued to improve key metrics — including subscription margin and overall gross margin — while also announcing partnerships and products that are expected to deliver meaningful growth,&#8221; said Rick Wilmer, CEO at ChargePoint. 
Outlook:&nbsp;ChargePoint sees&nbsp;second-quarter revenue in a range of&nbsp;$90 million to $100 million, versus the $108.07 million&nbsp;analyst estimate.
CHPT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ChargePoint stock was down 10.12% at 79 cents in Wednesday's extended trading after climbing 13.16% in the regular session.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

After-Hours Center

Tech

CHPT

ChargePoint Stock Sinks After Q1 Revenues Miss, Weak Q2 Guidance: Details

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) ("Rivian") today announced that Rivian Holdings, LLC (the "Company"), Rivian, LLC ("Rivian LLC") and Rivian Automotive, LLC ("Rivian Automotive" and, together with the Company and Rivian LLC, the "Co-Issuers") priced their private offering of $1,250,000,000 aggregate principal amount of 10.000% senior secured green notes due 2031 (the "notes"). Rivian expects to use the net proceeds from the offering of the notes, together with cash on hand, to redeem in full the $1,250,000,000 aggregate principal amount of the Co-Issuers' outstanding floating rate senior secured notes due 2026 (the "2026 Notes") and pay related fees and expenses. This press release does not constitute a notice of redemption with respect to the 2026 Notes.

Offerings

RIVN

Rivian Prices $1.25B Private Offering Of 10% Senior Secured Green Notes Due 2031

Kuke Music Holding Limited, a Cayman Islands exempted company, a leading classical music service platform in China, (the "Company") entered into a securities purchase agreement, in connection with the issuance and sale of an aggregate of 8,030,000 American Depositary Shares at a purchase price of $3.54 per American Depositary Share, representing 80,300,000 Class A ordinary shares.

KUKE

Kuke Music Holding Entered Into Securities Purchase Agreements For Sale Of 8.03M Shares At $3.54/Share

Anthony Meeker to Continue as Director
VANCOUVER, Wash., June 04, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (BBSI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., today announced that Joseph S. Clabby has been appointed Chairman of the Board of Directors. He succeeds Tony Meeker, who will continue to serve as a member of the board.

Management

BBSI

Barrett Business Services Appoints Joseph S. Clabby As Chairman Of The Board, Succeeding Tony Meeker Who Will Remain On The Board As Director

Insider Trades

CBUS

Cibus Chairman Rory Riggs Interest In Purchasing Up To $10M In Public Offering Is Non-Binding And Final Offering Remains Subject To Market Conditions And Uncertainty

WIIM

Cibus shares are trading lower after the company announced a proposed public offering.

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) sees Q1 sales of $99.000 million-$101.000 million vs $127.83 million analyst estimate.

BARK

BARK Sees Q1 Sales $99.000M-$101.000M vs $127.83M Est

On June 4, 2025, Nelnet, Inc. ("Nelnet") received cash proceeds of $411 million as a result of redeeming certain of its membership interests of ALLO Holdings LLC ("ALLO") under a Membership Unit Redemption Agreement previously reported on a Current Report on Form 8-K filed on April 21, 2025.
 &nbsp;
As part of this transaction, Nelnet redeemed a portion of its voting membership interests of ALLO and all its outstanding preferred membership interests, including the preferred return accrued on such membership interests through June 3, 2025. As a result of the redemption, Nelnet recognized a pre-tax gain of $175 million.
 &nbsp;
Immediately following the closing of the transaction, Nelnet no longer owns any preferred membership interests of ALLO, but maintains a significant voting equity investment in ALLO. Nelnet's ownership of ALLO decreased from 45% to 27%. Nelnet will continue to account for its remaining 27% voting membership interests of ALLO under the Hypothetical Liquidation at Book Value (HLBV) method of accounting, with a carrying value of $0.

Contracts

Nelnet Redeems ALLO Holdings Membership Interests For $411M, Realizes $175M Pre-Tax Gain, Reduces Ownership From 45% To 27%

Cibus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) (the "Company" or "Cibus"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock (or common stock equivalents in lieu thereof) in a public offering. All of the securities to be sold in the offering are to be offered by Cibus. The Chairman of Cibus' board of directors, Mr. Rory Riggs, has indicated an interest in purchasing up to $10.0 million of shares of Class A common stock and/or common stock equivalents in this offering. Because such an indication of interest is not a binding agreement or commitment to purchase, Mr. Riggs may elect not to purchase any shares in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering to fund further development of the Company's weed management productivity traits in Rice and for working capital and general corporate purposes, as it pursues longer-term financing.

Cibus Announces Public Offering Of Class A Common Stock; Chairman Rory Riggs Signals Interest In Up To $10M Purchase Of Shares Of Class A Common Stock And/Or Common Stock Equivalents In This Offering

Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) reported first-quarter financial results Wednesday after the market close. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/06/g45780121/five-below-inc-announces-first-quarter-fiscal-2025-financial-results">from the quarter</a>.
<ul class="wp-block-list">
<li>Q1 Revenue:&nbsp;$970.5 million, versus&nbsp;<a href="https://www.benzinga.com/quote/FIVE/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $966.49 million</li>
<li>Q1 Adjusted EPS:&nbsp;86 cents, versus estimates of 82 cents</li>
</ul>
Total revenue was up 19.5% year-over-year, while comparable sales increased 7.1% year-over-year. The company reported operating income of $50.8 million in the first quarter.&nbsp;
Five Below opened 55 new stores in the quarter, bringing total locations up to 1,826 at quarter's end. The company ended the period with $427.46 million in cash and cash equivalents.
&#8220;Our&nbsp;first quarter&nbsp;results demonstrate the effectiveness of our strategy, grounded in trend-right product, extreme value and a fun store experience. We were pleased to see broad-based strength across the majority of our merchandising worlds, resulting in a transaction-driven&nbsp;7.1%&nbsp;increase in comparable sales, as well as strong performance from our new stores,&#8221; said&nbsp;Winnie Park, CEO of Five Below.
The company noted that CFO Kristy Chipman has decided to step down from her roles for personal reasons. COO Ken Bull will take on the role of interim CFO as the company searches for a replacement.
Outlook:&nbsp;Five Below expects second-quarter revenue in the range of $975 million to $995 million versus estimates of $958.31 million. The company anticipates second-quarter adjusted earnings of 50 cents to 62 cents per share versus estimates of 56 cents per share.&nbsp;
Five Below also raised guidance for full-year 2025. The company sees full-year revenue of $4.33 billion to $4.42 billion, up from prior guidance of $4.21 billion to $4.33 billion. The company expects full-year adjusted earnings to be between $4.25 and $4.72 per share, up from prior guidance of $4.10 to $4.72 per share. Analysts currently anticipate full-year revenue of $4.37 billion and earnings of $4.76 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;Looking ahead, this unwavering focus on the core customer combined with disciplined execution of our strategy and the agility of our teams position us to deliver our financial and operational objectives as we navigate the impact of tariffs and the associated uncertainty in the current global trade environment,&#8221; Park said.
Five Below executives will further discuss the quarter on a call with investors and analysts at 4:30 p.m. ET.
FIVE Price Action: <a href="http://benzinga.com/quote/five" target="_blank" rel="noreferrer noopener">Five Below shares</a> were up 0.63% in after-hours, trading at $123.83 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45748544/walmart-leverages-automation-and-ai-to-cut-costs-and-grow-paving-the-way-for-other-retailers-report">Walmart Leverages Automation And AI To Cut Costs And Grow, Paving The Way For Other Retailers: Report</a></li>
</ul>
Photo: Retail Photographer/Shutterstock.

FIVE

Five Below Q1 Earnings: Revenue, EPS Beat, Retailer Raises Guidance, CFO Will Step Down

XELB

Xcel Brands shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is looking for Q2 Adj EPS of $1.85-2.00 vs $2.46 analyst estimate..

PVH Sees Q2 Adj EPS $1.85-2.00 vs $2.46 Est

ChargePoint Holdings shares are trading lower after the company reported worse-than-expected Q1 sales results and issued Q2 sales guidance below estimates.

With the broader technology sector enjoying a resurgence, several of the usual suspects have benefited tremendously from the momentum spike. Still, Teradyne Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), a leading supplier of automated test equipment (ATE) and industrial automation solutions, has lagged its innovation-centric peers. At the same time, the potential trickle-down effect could lift TER stock, making it both a possible value investment and an intriguing trade.
Recently, the tech-oriented Nasdaq Composite eked into positive territory for the year, symbolizing the resurgence that has taken place among publicly traded innovators. Over the past 52 weeks, the index has now gained over 15%. Terdayne, though, has not shared in the enthusiasm. On a year-to-date basis, TER stock is down more than 34%. Over the past 52 weeks, it has lost nearly 41%.
Nevertheless, there's legitimate cause for optimism. Semiconductor juggernauts like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) have regained their mojo in recent sessions. Part of the enthusiasm could be traced to catalysts such as the "TACO" trade, a crude acronym that stands for ‘Trump Always Chickens Out.'
Essentially, the market is digesting President Donald Trump's tariff policies and accompanying aggressive rhetoric. Initially, the tariffs sparked great concern among investors, leading to severe volatility. However, Trump has a tendency of <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45715677/tom-lee-bets-on-a-new-bull-market-as-trumps-tariff-retreat-fuels-taco-trade-amid-run-it-hot-optimism">talking tough first and then walking back the bravado</a>. The market has noticed and is responding accordingly.
Subsequently, concerns about the impact of retaliatory measures against the tech sector has lessened somewhat. Combined with <a href="https://www.benzinga.com/news/25/05/45671751/amd-stock-rises-on-nvidias-blowout-quarter-and-ai-momentum">strong earnings results</a> from the semiconductor space, the landscape appears compelling for TER stock. Fundamentally, that's because advanced chips are incredibly complex, requiring rigorous testing protocols. Since this process represents Teradyne's bread and butter, TER presents an intriguing value proposition.
It also might make for a quick trade.
<h2 class="wp-block-heading">A Sentiment Reversal Could Be Due For TER Stock</h2>
To be completely fair, the <a href="https://www.benzinga.com/news/24/08/40422222/teradyne-positioned-for-ai-growth-with-strong-robotics-and-auto-test-markets-analyst-upgrades-stock">fundamental argument</a> that Teradyne's behind-the-scenes relevance should boost its business was mentioned last year. As stated earlier, TER stock has lost a massive amount of equity value since that argument was issued. This goes to show how investing narratives — no matter how convincing — aren't necessarily the best predictors.
On the flipside, when it comes to the discipline of trading, predictability runs at the heart of the speculative practice. Traders aren't necessarily focused on the narratives, though they provide important context. Storylines represent the "why" of a target enterprise or asset. Traders are focused on the "how" — how much, how fast, how likely.
In other words, the central theme in options is probability: how likely is it that a particular stock will meet its profitability threshold within an allocated time period? To answer this question, traders should turn to market breadth or the assessment of patterns of accumulation and distribution.
Ordinarily, financial experts will turn to fundamental and technical analysis to aid in their decision-making process. Unfortunately, these methodologies are only partially useful because of their property of non-stationarity. That's the academic way of saying that core metrics such as earnings growth or share price generally fluctuate, especially across vast time periods and sentiment regimes.
For example, TER stock was trading around $20 a share a decade ago. It's above $82 today, meaning that statistical clustering is really only applicable for a narrow time range. In contrast, market breadth is simply demand and demand is a binary construct. Such constructs existed in 2015 and they're applicable today.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04152119/TER-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-938723" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04152119/TER-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04152119/TER-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04152119/TER-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04152119/TER-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
In the past two months, TER stock printed a "3-7-D" market breadth sequence: three up weeks, seven down weeks, with a net negative trajectory across the 10-week period. Notably, in 60.71% of cases, the following week's price action results in upside, with a median return of 5.25%. Based on Friday's close of $78.60, TER is on track to hit $82.73, which is now a very realistic target.
Should the bulls maintain control of the market, the median return for the second week stands at 2.75%. If so, that should push TER stock a hair over the $85 level.
<h2 class="wp-block-heading">Getting Down To Business</h2>
Using the above market intelligence, the most rational multi-leg options strategy may be the 80/85 bull call spread expiring June 20. This transaction involves buying the $80 call and simultaneously selling the $85 call, for a net debit paid of $270. Should TER stock rise through the short strike price at expiration, the maximum reward is $230, a payout of over 85%.
Primarily, what makes this trade attractive is the implied shift in sentiment. In any given week, the chance that a long position in TER stock will be profitable is 54.04%. As it stands, bullish traders have a modest edge. Coming off the back of the 3-7-D sequence, these traders enjoy an extra boost in probability, thus incentivizing a debit-based strategy.
Read Next:
<a href="https://www.benzinga.com/markets/options/25/06/45757550/tsla-stock-elon-musk-return-probabilistic-bullish-edge">Options Corner: Tesla Offers A 65% Probabilistic Edge That Favors The Bullish Trader</a>
Photo: Shutterstock

Equities

Long Ideas

Options

NVDA

Options Corner: Teradyne's Value Proposition Also Bodes Well For Swing Traders

Transocean Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) ("Transocean") today announced that a two-well option was exercised for the Transocean Spitsbergen in Norway. The program is expected to commence in the first quarter of 2026 in direct continuation of the rig's current program and contribute approximately $100 million in backlog, excluding additional services.

Transocean Secures $100M Contract Extension For Spitsbergen Rig In Norway, With Two-Well Program Set To Begin In Early 2026

Press Releases

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

Comments

Tourmaline Bio

Notizie

Ultime notizie per Tourmaline Bio (NASDAQ:TRML) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO